Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLEIADES
NCT03412565Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03412565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412565.